212 related articles for article (PubMed ID: 32245803)
1. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
3. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
4. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
5. ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer.
Wang Z; Katsaros D; Biglia N; Shen Y; Loo L; Yu X; Lin H; Fu Y; Chu WM; Fei P; Ni Y; Jia W; Deng X; Qian B; Yu H
Breast Cancer Res Treat; 2019 Jun; 175(2):353-368. PubMed ID: 30830488
[TBL] [Abstract][Full Text] [Related]
6. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.
Guo S; Li Y; Tong Q; Gu F; Zhu T; Fu L; Yang S
PLoS One; 2012; 7(12):e52380. PubMed ID: 23285017
[TBL] [Abstract][Full Text] [Related]
7. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
[TBL] [Abstract][Full Text] [Related]
8. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
[TBL] [Abstract][Full Text] [Related]
10. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
11. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
12. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
13. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
14. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
[TBL] [Abstract][Full Text] [Related]
15. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
19. BQ323636.1, a Novel Splice Variant to
Gong C; Man EPS; Tsoi H; Lee TKW; Lee P; Ma ST; Wong LS; Luk MY; Rakha EA; Green AR; Ellis IO; Lam EW; Cheung KL; Khoo US
Clin Cancer Res; 2018 Aug; 24(15):3681-3691. PubMed ID: 29420220
[No Abstract] [Full Text] [Related]
20. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.
He H; Sinha I; Fan R; Haldosen LA; Yan F; Zhao C; Dahlman-Wright K
Oncogene; 2018 May; 37(19):2586-2600. PubMed ID: 29467493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
